uniQure Corp - חובות ארוכי טווח של החברה QURE

This chart of uniQure N.V. (QURE) trading reflects long-term debt amounting to 0.56. The company maintains a stable R&D workforce while selectively recruiting specialized experts. As a leader in gene therapy, uniQure N.V. (QURE) brings together global geneticists to combat orphan diseases. Financial stability is supported by the sales of an innovative Hemophilia B treatment and partner licensing royalties.

This indicator captures the total volume of confirmed obligations with a maturity of more than one year, allowing for an objective assessment of the issuer's debt load and financial stability. By analyzing the long-term debt levels of the company, an investor determines the ability of uniQure N.V. (QURE) to fund costly R&D processes and retain key vectorology specialists without the risk of a sudden loss of access to capital.